English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Introduction. Osteoporosis is a serious problem, since about 50% of women  over the age of 50 suffer at least one osteoporotic fracture. Objective. The  aim of this study was to evaluate compliance as well as the efficiency and  safety of ibandronate treatment over a 6-month period in reducing the risk of  subsequent fracture in women with postmenopausal osteoporosis. Methods. A  multicenter, prospective, observational study was conducted during one year  in thirteen medical centres in Serbia. In the first part of the study the  participants received ibandronate tablets (150 mg) once a month for six  months. In the second part, the patients were under clinical follow-up.  Results. The mean age of the 184 menopausal women included in the study was  66.2±9.4 years. In 40.2% of the subjects the disease had been clinically  manifest during the five preceding years. The mean T-score value at the onset  of our investigation was -3.1±0.84 in 160 (87%) patients who were diagnosed  osteoporosis. Compression vertebral fractures alone were noted in 24% of the  women, spontaneous nonvertebral fractures in 49.4% and both in 4.9%. A  history of osteoporotic fractures was much more common in patients with three  or four risk factors (p=0.001). Out of 39 adverse events during therapy with  once monthly bisphosphonates only 2 (3.3%) were classified as severe. During  the treatment, spontaneous fractures occurred in 13 (7.1%) patients.  Conclusion. Ibadronate treatment once a month for 6 months was shown to be  very safe, tolerated well and without more serious side effects

srpski arhiv za celokupno lekarstvo

Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: Orpheum study